{"id":5173,"date":"2021-11-10T07:00:00","date_gmt":"2021-11-10T07:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2021\/"},"modified":"2021-11-10T07:00:00","modified_gmt":"2021-11-10T07:00:00","slug":"nanexa-publicerar-delarsrapport-for-januari-september-2021","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2021\/","title":{"rendered":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari \u2013 september 2021"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Betydande ordrar och paus i NEX-18-studien<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p><strong>V\u00e4sentliga h\u00e4ndelser under tredje kvartalet 2021<\/strong><\/p>\n<ul>\n<li>Nanexa slutf\u00f6rde under juli den fullt garanterade f\u00f6retr\u00e4desemission som beslutats i juni 2021, med st\u00f6d av bemyndigande fr\u00e5n \u00e5rsst\u00e4mman, vilket tillf\u00f6rde bolaget 107 miljoner kronor efter emissionskostnader.<\/li>\n<li>Europeiska patentverket (EPO) meddelade i juli avsikten att bevilja ett europeiskt patent avseende Nanexas PharmaShell\u00ae-teknologi.<\/li>\n<li>Nanexa erh\u00f6ll tv\u00e5 ordrar f\u00f6r ytbehandling av ett st\u00f6rre antal sensorer f\u00f6r detektion av radioaktiva isotoper av \u00e4delgasen xenon, fr\u00e5n tv\u00e5 amerikanska kunder till ett sammanlagt v\u00e4rde av cirka 1,7 miljoner kronor.<\/li>\n<li>Nanexa beslutade i slutet av september att pausa inkluderingen av patienter i bolagets fas I-studie med NEX-18, en dep\u00e5beredning av 5-azacitidin, p\u00e5 grund av m\u00e5ttliga hudreaktioner vid injektionsst\u00e4llet. En utredning av orsaken inleddes tillsammans med klinikerna som deltar i studien.<\/li>\n<\/ul>\n<p><strong>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/strong><\/p>\n<ul>\n<li>Nanexa mottog beslut fr\u00e5n Finansinspektionen att betala sanktionsavgift om 1 000 000 kronor avseende en h\u00e4ndelse som intr\u00e4ffade 2017.<\/li>\n<li>Nanexa tecknade ytterligare ett s\u00e5 kallat Material Transfer and Feasibility Study Agreement med en av bolagets befintliga kunder, f\u00f6r utv\u00e4rdering av PharmaShell\u00ae-teknologin med en specifik biologisk l\u00e4kemedelssubstans.<\/li>\n<li>Kompletterande prekliniska studier inleddes i oktober f\u00f6r att utreda vad som har orsakat de m\u00e5ttliga hudreaktioner som uppkom i bolagets fas I-studie med NEX-18, en dep\u00e5beredning av 5-azacitidin.<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 juli \u2013 30 september 2021<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 826 (530) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -7 857 (-3 814) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -7 904 (-3 894) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,18 (-0,18) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: 91 203 (-8 098) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 119 799 (25 990) kSEK<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 januari \u2013 30 september 2021<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 1 704 (1 819) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -22 776 (-13 713) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -22 912 (-13 914) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,75 (-0,71) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: 107 108 (14 612) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 119 799 (25 990) kSEK<\/li>\n<\/ul>\n<p><em>Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><\/p>\n<p>Rapporten i sin helhet finns tillg\u00e4nglig p\u00e5 v\u00e5r hemsida via f\u00f6ljande l\u00e4nk, <a href=\"https:\/\/nanexa.com\/finansiella-rapporter\/\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/nanexa.com\/finansiella-rapporter\/<\/a>.  <\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" target=\"_blank\" rel=\"nofollow noopener\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" target=\"_blank\" rel=\"nofollow noopener\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag fokuserat p\u00e5 utvecklingen av PharmaShell\u00ae, ett nytt och banbrytande drug delivery-system med stor\u00a0potential inom ett flertal substanstyper och indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae utvecklar Nanexa egna produkter och har samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland\u00a0AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a href=\"https:\/\/storage.mfn.se\/b3c128aa-22c9-4bff-9761-862ffd174f29\/nanexa-delarsrapport-jan-sep-2021.pdf\" class=\"mfn-primary\" target=\"_blank\" rel=\"nofollow noopener\">Nanexa Del\u00e5rsrapport Jan Sep 2021<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Betydande ordrar och paus i NEX-18-studien<\/p>\n","protected":false},"template":"","class_list":["post-5173","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report-interim-q3_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa publicerar del\u00e5rsrapport f\u00f6r januari \u2013 september 2021 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2021\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari \u2013 september 2021 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Betydande ordrar och paus i NEX-18-studien\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2021\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2021\\\/\",\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari \u2013 september 2021 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2021-11-10T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2021\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2021\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari \u2013 september 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari \u2013 september 2021 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2021\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari \u2013 september 2021 - Nanexa AB","og_description":"Betydande ordrar och paus i NEX-18-studien","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2021\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2021\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2021\/","name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari \u2013 september 2021 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2021-11-10T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2021\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2021\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari \u2013 september 2021"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/5173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=5173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}